- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Longeveron Announces Up To $17.5 Million Public Offering | 3 | GlobeNewswire (USA) | ||
| Fr | Longeveron Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| Mo | Longeveron launches offering of up to 11.8M shares via warrants and stock units | 4 | Seeking Alpha | ||
| Mo | Longeveron Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 21.07. | Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease | 3 | GlobeNewswire (USA) | ||
| 09.07. | Longeveron Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.07. | Longeveron stock soars after FDA approves IND for heart failure treatment | 4 | Investing.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 08.07. | Longeveron receives FDA approval for pediatric heart therapy IND | 2 | Investing.com | ||
| 08.07. | Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) | 269 | GlobeNewswire (Europe) | Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric... ► Artikel lesen | |
| 26.06. | Longeveron Appoints Than Powell as Chief Business Officer | 142 | GlobeNewswire (Europe) | Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology... ► Artikel lesen | |
| 24.06. | Longeveron schließt Patientenrekrutierung für pädiatrische Herzstudie zu HLHS ab | 1 | Investing.com Deutsch | ||
| 24.06. | Longeveron completes enrollment in HLHS pediatric heart trial | 1 | Investing.com | ||
| 24.06. | Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 97 | GlobeNewswire (Europe) | Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval... ► Artikel lesen | |
| 20.06. | Longeveron Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 16.06. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Longeveron to Attend BIO International Convention 2025 | 7 | GlobeNewswire (USA) | ||
| 12.05. | Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient | 3 | GlobeNewswire (USA) | ||
| 08.05. | Longeveron Q1 2025 slides: promising clinical data amid financial headwinds | 1 | Investing.com | ||
| 08.05. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update | 132 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
| CUREVAC | 4,660 | -0,09 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,800 | -1,27 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
| OCUGEN | 0,860 | +0,42 % | Ocugen sichert sich 20 Millionen US-Dollar über registrierte Direktplatzierung | ||
| CYTODYN | 0,222 | -4,31 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,039 | +7,22 % | SOL Global Investments Corp.: SOL Global Announces Listing on OTC Markets Under OTCID: SOLCF | Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to announce that its common shares... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 9,820 | +3,22 % | Anavex Life Sciences Corp.: Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 | ||
| CERUS | 1,077 | +3,16 % | Cerus raises 2025 revenue outlook to $200M-$203M driven by strong IFC demand | ||
| WINDTREE THERAPEUTICS | 0,545 | -7,16 % | Windtree Therapeutics: Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,950 | -0,51 % | RedChip Companies, Inc.: Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / August 8, 2025 / RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,450 | -1,75 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board | Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates... ► Artikel lesen | |
| ENTERA BIO | 1,490 | -6,05 % | Entera Bio Ltd.: Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates | FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,016 | -1,24 % | Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB | Today on 3 July 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting.
Resolution regarding approval of the board of... ► Artikel lesen | |
| QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,620 | -1,34 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,590 (-46,46 %) liegt der Kurs bei 0,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.